CD301 antibody targets the CD301 molecule, also known as CLEC10A (C-type lectin domain-containing 10A) or human macrophage galactose-type C-type lectin (MGL). CD301 is a transmembrane protein belonging to the C-type lectin receptor family, characterized by carbohydrate recognition domains that bind glycans terminating in galactose or N-acetylgalactosamine (Gal/GalNAc). It is primarily expressed on antigen-presenting cells (APCs), including dendritic cells (DCs) and macrophages, where it plays a role in immune modulation, pathogen recognition, and cellular interactions.
CD301 is implicated in promoting Th2-type immune responses, tolerance induction, and anti-inflammatory signaling. It binds to glycan structures on pathogens, tumor-associated antigens, and apoptotic cells, facilitating their uptake and processing. CD301 antibodies are widely used in research to identify specific subsets of APCs, particularly M2-polarized macrophages or regulatory DCs, in contexts like cancer, allergy, and autoimmune diseases. Studies also explore its therapeutic potential, as targeting CD301 may influence immune tolerance in cancer immunotherapy or inflammatory disorders.
In mice, homologous receptors (MGL1/MGL2) share functional similarities, aiding translational research. CD301 antibodies thus serve as critical tools for dissecting immune cell heterogeneity and glycan-mediated immune regulation.